Table 2.
Clinical characteristics of samples and classifier performance
| TX-TOTHILL | TX-YOSHIHARA | |
|---|---|---|
| Training set | Test set | |
| number of patients | 145 | 71 |
| no relapse > 22 months (sensitive) | 63 | 42 |
| relapse < 12 months (resistant) | 82 | 29 |
| average PFS | 21.69 +/− 21.47 | 25.86 +/− 21.68 |
| PFS, sensitive group | 39.33 +/− 22.40 | 40.21 +/− 16.72 |
| PFS, resistant group | 8.13 +/− 2.77 | 5.07 +/− 3.09 |
| FIGO stage | ||
| early stage (I-IIA) | 15 | 0 |
| advanced stage (IIB-IV) | 130 | 71 |
| Chemotherapy | ||
| platinum-based drug | 29 | 0 |
| platinum-based drug and taxanes | 116 | 71 |
| array platform | Affymetrix Human Genome U133 Plus 2.0 | Agilent Whole Human Genome Microarray 4x44K |
| optimism corrected AUC | 0.786 | 0.721 |
Clinical characteristics of the patient samples used in transcriptomics profiling and performance of the prognostic transcript panel classifier in identifying sensitive and resistant specimens